Menu Back toPragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum


Overview

In this comprehensive training course learn contemporary principles, regulatory expectations, and practical approaches to drug safety and pharmacovigilance in key regulatory jurisdictions, with a focus on the US and EU. The course curriculum is designed for the basic to intermediate level professional, and the topics will span the life cycle of traditional innovative medicinal products, from first-in-human through the postmarketing phase. This blended learning course employs a mixture of precourse online learning, informative instructional sessions, real-world case studies, and hands-on interactive exercises where learners can apply what they learn.


Join us at the co-located Boston DIA Member Appreciation Reception and Kickoff for DIA 2018 on August 14, 5:30-7:45PM!

What you will learn

  • Legal and regulatory basis for safety obligations, including a historical perspective
  • Principles, basic definitions, and pragmatic approaches for compliance
  • Basics of Individual Case Safety Reports (ICSRs) and periodic reports (DSUR, IND, AR, PADER, PSUR/PBRER) in the premarketing, peri-approval, and postmarketing continuum  
  • Evaluation of seriousness, expectedness and causality
  • Data collection, processing, and requirements in the postmarketing phase, including MedDRA coding, safety query development, and evolving regulatory requirements
  • Overview of case processing and organization of a typical safety department
  • Safety audits and inspections
  • Introduction to signal detection
  • Introduction to benefit-risk assessment
  • Basics of risk management planning, EU Risk Management Plans, and Risk Evaluation and Mitigation Strategies (REMS)

Who should attend?

This program is designed for entry through intermediate level professionals involved in:

  • Drug safety/pharmacovigilance
  • Adverse event reporting
  • Case processing
  • Safety evaluation
  • Periodic safety reporting
  • Medical monitoring
  • Quality systems
  • Regulatory strategy, regulatory affairs
  • Risk management planning and development of formal Risk Management Plans and REMS
  • Disciplines that interact with or support safety and pharmacovigilance functions across the product life cycle

Broadening their role within premarket or postmarket safety and pharmacovigilance functions

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Identify the history, principles, and regulatory framework for clinical trials and postmarketing safety
  • Discuss the basic definitions of terms used in day-to-day pharmacovigilance work
  • Recognize basic international regulatory requirements for safety surveillance, as well as those requirements specific for the US and EU
  • Describe the criteria and elements of expedited and periodic reporting of drug safety information from first-in-human studies through the postmarketing phase
  • Demonstrate an awareness of risk management and signal detection principles

Contact us

Registration Questions?

Send Email
1.888.257.6457
+1.215.442.6100


Co-Located Reception | Aug. 14

Boston DIA Member Appreciation Reception and Kickoff for DIA 2018


Agenda and Event Logistics

Send Email
+1.215.442.6108